According to the CDC, Venous Thromboembolism affects about 900,000 people (1 to 2 per 1,000) each year in the United States, however, the exact number is unknown; with around 60,000-100,000 deaths. It is observed that nearly one-third to one-half of the affected Deep vein thrombosis patients develop long-term complications due to damages in the valves due to clots. The Venous Thromboembolism treatment approaches aim to break the clots and prevent their further development. It majorly comprises blood-thinning agents such as medication. In advanced stages, mechanical devices and surgical treatment are also considered.
The available treatment options are often associated with severe side effects. To overcome the existing challenges and to meet the unmet needs, several pharmaceutical companies including Tetherex Pharmaceuticals, Ono Pharmaceutical, Quercis Pharma, Verseon Corporation, Velox Therapeutics, and others are diligently involved in developing innovative therapies for Venous Thromboembolism. As per DelveInsight, with the launch of emerging therapies, the Venous thromboembolism Market is expected to witness an exponential boom in the coming years.
Read more: Key Pharmaceutical Companies in the Venous Thromboembolism Market